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Pluripotent stem cell (PSC) culture using the xeno-free Essential 8™ Medium/truncated recombinant human 
Vitronectin system has been shown to support normal PSC properties and provide a large pool of cells for 
disease modeling and drug development. As research moves from translational to clinical research, general 
regulatory guidance from the US Food and Drug Administration (FDA) indicates that, cGMP manufactured, or 
clinical grade reagents should be used whenever available as ancillary reagents to minimize downstream risk to 
patients. Thus, we sought to identify regulatory compliant, animal-originfree alternatives for growth factors 
contained within the Essential 8™ Medium and incorporate ISO13485 manufacturing for the recombinantly 
expressed, truncated human Vitronectin (rhVTN-N), producing a qualified ancillary system for PSC expansion. 
Here we present data to support a seamless transition from the xeno-free Essential 8™ Medium system to the 
Cell Therapy Systems (CTS™) animal-origin free system. Compatibility is shown with existing cGMP-
manufactured passaging reagents: Versene Solution for clumped cell passaging and CTS™ TrypLE™ Select 
combined with RevitaCell™ Supplement for single cell passaging. Upon expansion, PSCs are shown to 
maintain normal PSC properties, including morphology, pluripotency, karyotype, and trilineage differentiation 
potential. Together this system provides a consistent, feeder-free PSC culture medium for translational and 
clinical research. 
 
